Platelet factor 4
Alternative Names: Endostatin B; Iroplact; PF4; Replistatin; RG 1001; rhPF 4; rPF4Latest Information Update: 25 Sep 2021
At a glance
- Originator Repligen
- Class Antineoplastics; Peptides
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Blood coagulation disorders; Colorectal cancer; Glioma; Kaposi's sarcoma; Malignant melanoma; Renal cancer
Most Recent Events
- 11 Nov 2003 Discontinued - Phase-II for Coagulation disorders in USA (IV)
- 11 Nov 2003 Discontinued - Phase-II for Colorectal cancer in USA (unspecified route)
- 11 Nov 2003 Discontinued - Phase-II for Glioma in USA (unspecified route)